Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.

CONCLUSIONS: In this small pilot study, prophylactic ranibizumab appears generally safe in patients treated with proton irradiation for choroidal melanoma. High rates of visual acuity retention were observed through 2 years. PMID: 27630373 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27630373?dopt=Abstract

Source: Transactions of the American Ophthalmological Society - July 31, 2016 Category: Opthalmology Authors: Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES Tags: Trans Am Ophthalmol Soc Source Type: research